Overview

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

Status:
Not yet recruiting
Trial end date:
2033-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate the safety and efficacy of the implantation of the LAmbre PlusTM device in patients with large or irregularly shaped appendages with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism compared to oral anticoagulation (OAC).
Phase:
N/A
Details
Lead Sponsor:
Brian O'Neill MD
Collaborator:
Lifetech Scientific (Shenzhen) Co., Ltd.
Treatments:
Apixaban
Betrixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin